Sunshine Gross Profit vs Operating Income Analysis
| SBFM Stock | USD 2.86 0.13 4.76% |
Sunshine Biopharma financial indicator trend analysis is much more than just breaking down Sunshine Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sunshine Biopharma is a good investment. Please check the relationship between Sunshine Biopharma Gross Profit and its Operating Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
Gross Profit vs Operating Income
Gross Profit vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sunshine Biopharma Gross Profit account and Operating Income. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Sunshine Biopharma's Gross Profit and Operating Income is -0.59. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Operating Income in the same time period over historical financial statements of Sunshine Biopharma, assuming nothing else is changed. The correlation between historical values of Sunshine Biopharma's Gross Profit and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of Sunshine Biopharma are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Gross Profit i.e., Sunshine Biopharma's Gross Profit and Operating Income go up and down completely randomly.
Correlation Coefficient | -0.59 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Gross Profit
Gross profit is a required income statement account that reflects total revenue of Sunshine Biopharma minus its cost of goods sold. It is profit before Sunshine Biopharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Operating Income
Operating Income is the amount of profit realized from Sunshine Biopharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Sunshine Biopharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Sunshine Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sunshine Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.At this time, Sunshine Biopharma's Selling General Administrative is very stable compared to the past year. As of the 2nd of December 2024, Tax Provision is likely to grow to about 428.6 K, though Issuance Of Capital Stock is likely to grow to (8.6 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 2.7M | 13.0M | 28.9M | 30.3M | Interest Expense | 328.8K | 39.4K | 137.3K | 148.9K |
Sunshine Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Sunshine Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sunshine Biopharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 98.1K | 1.0M | 2.2M | 29.2M | 27.3M | 28.7M | |
| Total Current Liabilities | 833.5K | 1.1M | 91.2K | 6.9M | 5.6M | 5.8M | |
| Total Stockholder Equity | (735.4K) | (954.8K) | 211.7K | 21.6M | 21.2M | 22.3M | |
| Net Debt | 675.1K | 923.2K | (145.2K) | (17.6M) | (15.6M) | (14.9M) | |
| Retained Earnings | (17.4M) | (20.2M) | (32.7M) | (59.4M) | (63.9M) | (60.7M) | |
| Accounts Payable | 96.9K | 62.9K | 42.9K | 2.8M | 2.6M | 2.7M | |
| Cash | 40.5K | 989.9K | 2.0M | 21.8M | 16.3M | 17.1M | |
| Cash And Short Term Investments | 40.5K | 989.9K | 2.0M | 21.8M | 16.3M | 17.1M | |
| Common Stock Shares Outstanding | 54.7K | 866.0 | 1.3K | 7.6K | 12.2K | 8.8K | |
| Liabilities And Stockholders Equity | 98.1K | 1.0M | 2.2M | 29.2M | 27.3M | 28.7M | |
| Non Current Liabilities Total | 812.5K | 949.0K | 1.9M | 685.3K | 587.8K | 480.3K | |
| Other Stockholder Equity | 16.6M | 19.2M | 32.8M | 80.8M | 84.4M | 88.6M | |
| Total Liab | 833.5K | 2.0M | 2.0M | 7.6M | 6.1M | 6.4M | |
| Total Current Assets | 65.7K | 1.0M | 2.2M | 27.3M | 24.9M | 26.1M | |
| Common Stock | 35.3K | 346.4K | 2.6K | 22.6K | 28.0K | 26.6K | |
| Short Long Term Debt Total | 715.6K | 1.9M | 1.9M | 4.3M | 657.7K | 1.0M | |
| Other Current Liab | 21.1K | 24.3K | 48.3K | 496.2K | 2.5M | 2.7M | |
| Other Current Assets | 8.8K | 10.4K | 37.2K | 283.8K | 310.6K | 326.1K | |
| Short Term Debt | 715.6K | 964.1K | 1.9M | 3.8M | 118.7K | 112.7K | |
| Net Tangible Assets | (105.8K) | (785.4K) | (1.1M) | 111.7K | 100.5K | 105.5K | |
| Short Long Term Debt | 662.8K | 715.6K | 964.1K | 3.6M | 4.2M | 4.4M | |
| Property Plant And Equipment Net | 32.5K | 19.5K | 7.1K | 1.2M | 1.0M | 1.1M | |
| Non Current Assets Total | 32.5K | 19.5K | 7.1K | 1.9M | 2.5M | 2.6M | |
| Net Receivables | 430.0 | 1.9K | 7.8K | 1.9M | 2.6M | 2.7M | |
| Accumulated Other Comprehensive Income | (2.5K) | (2.9K) | (23.1K) | 161.8K | 696.1K | 730.9K | |
| Property Plant Equipment | 45.1K | 32.5K | 19.5K | 7.1K | 8.1K | 7.7K | |
| Non Currrent Assets Other | (32.5K) | (19.5K) | (7.1K) | (1.9M) | (1.7M) | (1.7M) | |
| Net Invested Capital | (69.8K) | 858.3K | 2.0M | 25.3M | 21.2M | 22.3M | |
| Net Working Capital | (767.8K) | (25.4K) | 2.1M | 20.4M | 19.3M | 20.3M | |
| Capital Stock | 85.3K | 446.4K | 102.6K | 23.6K | 29.0K | 27.6K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.